FDA Approves Once-Weekly Sogroya for Turner Syndrome in Children
The U.S. Food and Drug Administration approved somapacitan-beco (Sogroya, Novo Nordisk) on Thursday as the first once-weekly growth hormone for children with Turner syndrome, expanding a treatment option that cuts … Read More